IDEAYA Biosciences 주식 주식분석 | 주식가격 | 뉴스 | IDYA | US45166A1025 | A2PJPB

날짜	IDEAYA Biosciences 주식 가격
	31.70 undefined
	30.73 undefined
	31.68 undefined
	30.80 undefined
	30.50 undefined
	30.37 undefined
	31.37 undefined
	33.73 undefined
	35.00 undefined
	35.28 undefined
	34.75 undefined
	35.78 undefined
	36.83 undefined
	37.46 undefined
	36.11 undefined
	36.20 undefined
	36.64 undefined
	36.45 undefined
	36.21 undefined
	37.37 undefined
	38.49 undefined

날짜	IDEAYA Biosciences 매출	IDEAYA Biosciences EBIT	IDEAYA Biosciences 이익
2030e	953.24 백만 undefined	499.54 백만 undefined	532.96 백만 undefined
2029e	1.18 조. undefined	414.39 백만 undefined	627.89 백만 undefined
2028e	715.9 백만 undefined	364.77 백만 undefined	260.02 백만 undefined
2027e	299.88 백만 undefined	15.97 백만 undefined	-39.85 백만 undefined
2026e	90.2 백만 undefined	-217.47 백만 undefined	-215.28 백만 undefined
2025e	16.66 백만 undefined	-231.87 백만 undefined	-250.72 백만 undefined
2024e	8.55 백만 undefined	-203.6 백만 undefined	-219.55 백만 undefined
2023	23.39 백만 undefined	-134.43 백만 undefined	-112.96 백만 undefined
2022	50.93 백만 undefined	-62.5 백만 undefined	-58.66 백만 undefined
2021	27.94 백만 undefined	-50.27 백만 undefined	-49.76 백만 undefined
2020	19.54 백만 undefined	-35.34 백만 undefined	-34.5 백만 undefined
2019	0 undefined	-44.27 백만 undefined	-41.98 백만 undefined
2018	0 undefined	-36.42 백만 undefined	-34.35 백만 undefined
2017	0 undefined	-14.44 백만 undefined	-11.86 백만 undefined

	매출	EBIT	이익
2017	0 USD	-14.44 백만 USD	-11.86 백만 USD
2018	0 USD	-36.42 백만 USD	-34.35 백만 USD
2019	0 USD	-44.27 백만 USD	-41.98 백만 USD
2020	19.54 백만 USD	-35.34 백만 USD	-34.5 백만 USD
2021	27.94 백만 USD	-50.27 백만 USD	-49.76 백만 USD
2022	50.93 백만 USD	-62.5 백만 USD	-58.66 백만 USD
2023	23.39 백만 USD	-134.43 백만 USD	-112.96 백만 USD
2024e	8.55 백만 USD	-203.6 백만 USD	-219.55 백만 USD
2025e	16.66 백만 USD	-231.87 백만 USD	-250.72 백만 USD
2026e	90.2 백만 USD	-217.47 백만 USD	-215.28 백만 USD
2027e	299.88 백만 USD	15.97 백만 USD	-39.85 백만 USD
2028e	715.9 백만 USD	364.77 백만 USD	260.02 백만 USD
2029e	1.18 조. USD	414.39 백만 USD	627.89 백만 USD
2030e	953.24 백만 USD	499.54 백만 USD	532.96 백만 USD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e
0	0	0	0.02	0.03	0.05	0.02	0.01	0.02	0.09	0.3	0.72	1.18	0.95
-	-	-	-	42.11	85.19	-54.00	-65.22	100.00	462.50	232.22	139.13	64.76	-19.10
-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0	0
-14	-36	-44	-35	-50	-62	-134	-203	-231	-217	15	364	414	499
-	-	-	-184.21	-185.19	-124.00	-582.61	-2,537.50	-1,443.75	-241.11	5.02	50.91	35.14	52.36
-11	-34	-41	-34	-49	-58	-112	-219	-250	-215	-39	260	627	532
-	209.09	20.59	-17.07	44.12	18.37	93.10	95.54	14.16	-14.00	-81.86	-766.67	141.15	-15.15
19.48	19.48	12.5	24.72	35.25	41.44	57.52	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

13.2	90	99	283.6	246.8	364.8	525.11
0	0	0	1.9	1.1	0.2	0.02
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.4	0.7	2.7	3.1	3.1	5.4	7.5
13.6	90.7	101.7	288.6	251	370.4	532.63
3.7	5.2	9.7	9.5	8.7	9	8.41
0	0	1.5	0	121.3	8.3	107.49
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
200	700	100	200	400	200	782
3.9	5.9	11.3	9.7	130.4	17.5	116.68
17.5	96.6	113	298.3	381.4	387.9	649.32

26.1	138.4	0	0	0	0	0.01
0.4	1.6	192.8	325.3	479	587.7	968.89
-16.2	-50.5	-92.5	-127	-176.7	-235.4	-348.36
0	0	100	0	-700	-2,900	562
0	0	0	0	0	0	0
10.3	89.5	100.4	198.3	301.6	349.4	621.09
0.7	1.4	0.7	1	2.1	4.3	6.6
1.3	3.6	6.2	10.1	14	18.9	20.5
0.5	0.4	0.1	27.6	29	8.6	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
2.5	5.4	7	38.7	45.1	31.8	27.1
3.2	0	0	0	0	0	0
0	0	0	0	0	0	0
1.5	1.7	5.7	61.4	34.7	6.8	1.13
4.7	1.7	5.7	61.4	34.7	6.8	1.13
7.2	7.1	12.7	100.1	79.8	38.6	28.23
17.5	96.6	113.1	298.4	381.4	388	649.32

2017	2018	2019	2020	2021	2022	2023
-11	-34	-41	-34	-49	-58	-112
0	0	1	1	1	2	2
0	0	0	0	0	0	0
1	1	0	84	-17	-41	-11
-2	5	3	7	18	22	25
0	0	0	0	0	0	0
0	0	0	0	0	0	0
-12	-27	-39	55	-55	-87	-115
-1	-1	-1	0	-2	-3	-2
-8	-63	2	-146	-69	-33	-158
-7	-61	3	-145	-67	-29	-156
0	0	0	0	0	0	0
0	0	0	0	0	0	0
17	105	50	108	145	97	362
17	105	50	128	145	97	362
0	0	0	19	0	0	0
0	0	0	0	0	0	0
-3	14	13	37	20	-23	89
-13.98	-29.33	-40.66	54.97	-58.42	-90.62	-117.59
0	0	0	0	0	0	0

IDEAYA Biosciences 브루토마진	IDEAYA Biosciences EBIT-마진	IDEAYA Biosciences 이익 마진
2030e	52.4 %	55.91 %
2029e	35.18 %	53.3 %
2028e	50.95 %	36.32 %
2027e	5.33 %	-13.29 %
2026e	-241.09 %	-238.66 %
2025e	-1,391.86 %	-1,505.03 %
2024e	-2,382.67 %	-2,569.37 %
2023	-574.85 %	-483.05 %
2022	-122.72 %	-115.18 %
2021	-179.92 %	-178.1 %
2020	-180.86 %	-176.56 %
2019	0 %	0 %
2018	0 %	0 %
2017	0 %	0 %

	EBIT-마진	이익 마진
2017	0 %	0 %
2018	0 %	0 %
2019	0 %	0 %
2020	-180.86 %	-176.56 %
2021	-179.92 %	-178.1 %
2022	-122.72 %	-115.18 %
2023	-574.85 %	-483.05 %
2024e	-2,382.67 %	-2,569.37 %
2025e	-1,391.86 %	-1,505.03 %
2026e	-241.09 %	-238.66 %
2027e	5.33 %	-13.29 %
2028e	50.95 %	36.32 %
2029e	35.18 %	53.3 %
2030e	52.4 %	55.91 %

날짜	IDEAYA Biosciences 주당 매출	IDEAYA Biosciences EBIT 당 주식	IDEAYA Biosciences 주당 이익
2030e	11.28 undefined	0 undefined	6.31 undefined
2029e	13.94 undefined	0 undefined	7.43 undefined
2028e	8.47 undefined	0 undefined	3.08 undefined
2027e	3.55 undefined	0 undefined	-0.47 undefined
2026e	1.07 undefined	0 undefined	-2.55 undefined
2025e	0.2 undefined	0 undefined	-2.97 undefined
2024e	0.1 undefined	0 undefined	-2.6 undefined
2023	0.41 undefined	-2.34 undefined	-1.96 undefined
2022	1.23 undefined	-1.51 undefined	-1.42 undefined
2021	0.79 undefined	-1.43 undefined	-1.41 undefined
2020	0.79 undefined	-1.43 undefined	-1.4 undefined
2019	0 undefined	-3.54 undefined	-3.36 undefined
2018	0 undefined	-1.87 undefined	-1.76 undefined
2017	0 undefined	-0.74 undefined	-0.61 undefined

	주당 매출	EBIT 당 주식	주당 이익
2017	0 USD	-0.74 USD	-0.61 USD
2018	0 USD	-1.87 USD	-1.76 USD
2019	0 USD	-3.54 USD	-3.36 USD
2020	0.79 USD	-1.43 USD	-1.4 USD
2021	0.79 USD	-1.43 USD	-1.41 USD
2022	1.23 USD	-1.51 USD	-1.42 USD
2023	0.41 USD	-2.34 USD	-1.96 USD
2024e	0.1 USD	0 USD	-2.6 USD
2025e	0.2 USD	0 USD	-2.97 USD
2026e	1.07 USD	0 USD	-2.55 USD
2027e	3.55 USD	0 USD	-0.47 USD
2028e	8.47 USD	0 USD	3.08 USD
2029e	13.94 USD	0 USD	7.43 USD
2030e	11.28 USD	0 USD	6.31 USD

	주식 수량
2017	19.48 백만 Aktien
2018	19.48 백만 Aktien
2019	12.5 백만 Aktien
2020	24.72 백만 Aktien
2021	35.25 백만 Aktien
2022	41.44 백만 Aktien
2023	57.52 백만 Aktien
2024e	57.52 백만 Aktien
2025e	57.52 백만 Aktien
2026e	57.52 백만 Aktien
2027e	57.52 백만 Aktien
2028e	57.52 백만 Aktien
2029e	57.52 백만 Aktien
2030e	57.52 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.55	-0.68 (-24.54 %)	2024 Q2
-0.52	-0.53 (-0.97 %)	2024 Q1
-0.48	-0.52 (-9.04 %)	2023 Q4
-0.5	-0.46 (8.82 %)	2023 Q3
-0.57	-0.5 (11.93 %)	2023 Q2
-0.56	-0.49 (12.52 %)	2023 Q1
-0.57	-0.5 (12.74 %)	2022 Q4
-0.63	0.04 (106.37 %)	2022 Q3
-0.53	-0.57 (-8.39 %)	2022 Q2
-0.42	-0.36 (14 %)	2022 Q1
-0.32	-0.47 (-48.12 %)	2021 Q4
-0.31	-0.31 (-1.31 %)	2021 Q3
-0.1	-0.33 (-216.4 %)	2021 Q2
-0.28	-0.28 (-1.19 %)	2021 Q1
-0.31	-0.18 (41.04 %)	2020 Q4
1.15	-0.17 (-114.8 %)	2020 Q3
1.86	-0.59 (-131.64 %)	2020 Q2
-0.59	-0.59 (-0.67 %)	2020 Q1
-0.58	-0.53 (9.37 %)	2019 Q4
-0.67	-0.54 (19.93 %)	2019 Q3
-0.66	-1.3 (-98.2 %)	2019 Q2

%-지분	이름	주식	변경
9.65933 %	Fidelity Management & Research Company LLC	8,160,206	7,271,997
5.62893 %	BlackRock Institutional Trust Company, N.A.	4,755,318	752,470
4.59706 %	Federated Hermes Global Investment Management Corp.	3,883,600	500,000
4.20442 %	Janus Henderson Investors	3,551,891	1,828,731
4.16903 %	T. Rowe Price Associates, Inc.	3,521,999	523,472
4.10191 %	The Vanguard Group, Inc.	3,465,297	504,275
3.54155 %	State Street Global Advisors (US)	2,991,899	844,399
3.46247 %	Adage Capital Management, L.P.	2,925,094	638,133
3.11351 %	Deerfield Management Company, L.P.	2,630,292	361,664
2.60750 %	Boxer Capital, L.L.C.	2,202,812	0
2.34004 %	Capital Research Global Investors	1,976,870	600,000
2.13068 %	Logos Global Management LLC	1,800,000	-450,000
2.04669 %	BVF Partners L.P.	1,729,043	-3,554,446
2.01247 %	Holocene Advisors, LP	1,700,135	667,204
1.94519 %	Citadel Advisors LLC	1,643,293	898,193
1.79924 %	Avidity Partners Management LP	1,520,000	-624,971
1.72690 %	Sofinnova Investments, Inc	1,458,881	421,694
1.59959 %	Geode Capital Management, L.L.C.	1,351,337	190,232
1.52261 %	Dimensional Fund Advisors, L.P.	1,286,300	144,058
1.25725 %	Baker Bros. Advisors LP	1,062,123	0
1.16933 %	Morgan Stanley & Co. LLC	987,851	844,492
1.10779 %	Redmile Group, LLC	935,863	935,863
1.08048 %	Driehaus Capital Management, LLC	912,786	215,325
1.03663 %	Pictet Asset Management Ltd.	875,747	211,657
0.80242 %	Hata (Yujiro S.)	677,887	0
0.78402 %	Platinum Asset Management	662,343	-104,339
0.66844 %	Soleus Capital Management, L.P.	564,700	564,700
0.63920 %	Candriam Luxembourg S.A.	540,000	145,000
0.63882 %	Fisher Investments	539,676	508,151
0.62970 %	Boone Capital Management LLC	531,967	-38,715
0.62678 %	D. E. Shaw & Co., L.P.	529,506	93,148
0.61120 %	Dafna Capital Management, LLC	516,341	16,521
0.60601 %	Northern Trust Investments, Inc.	511,956	61,264
0.58766 %	Charles Schwab Investment Management, Inc.	496,456	59,100
0.58007 %	Ensign Peak Advisors, Inc.	490,039	126,255
0.55193 %	Balyasny Asset Management LP	466,271	466,271
0.53267 %	Cormorant Asset Management, LP	450,000	-150,000
0.49013 %	Woodline Partners LP	414,059	173,631
0.46759 %	Candriam Belgium S.A.	395,019	-35,000
0.45263 %	First Turn Management, LLC	382,382	382,382
0.44589 %	Nuveen LLC	376,692	-169,061
0.41364 %	Medical Strategy GmbH	349,447	-3,400
0.41014 %	Victory Capital Management Inc.	346,490	346,490
0.40918 %	First Light Asset Management, LLC	345,674	345,674
0.39654 %	Eventide Asset Management, LLC	335,000	0
0.36873 %	Opaleye Management Inc.	311,500	0
0.36574 %	BlackRock Financial Management, Inc.	308,979	61,814
0.29746 %	Superstring Capital Management LP	251,295	251,295
0.28797 %	AXA Investment Managers UK Ltd.	243,280	-100,475
0.26532 %	Columbia Threadneedle Investments (US)	224,141	-49,332
0.26037 %	Voya Investment Management LLC	219,957	-71,119
0.24671 %	Goldman Sachs & Company, Inc.	208,417	-109,529
0.24590 %	BNP Paribas Securities Corp. North America	207,735	155,179
0.23661 %	Walleye Capital LLC	199,891	115,928
0.23240 %	UBS Asset Management (Americas), Inc.	196,329	-2,262
0.23069 %	Invesco Capital Management LLC	194,886	-72,891
0.22888 %	Rafferty Asset Management LLC	193,356	64,280
0.21626 %	BofA Global Research (US)	182,695	100,942
0.20885 %	Barclays Bank PLC	176,440	90,114
0.19846 %	BlackRock Investment Management, LLC	167,656	22,622
0.18582 %	Morgan Stanley Investment Management Inc. (US)	156,983	155,836
0.18172 %	BNY Mellon Asset Management	153,513	11,507
0.17839 %	UBS Financial Services, Inc.	150,702	94,167
0.16489 %	Nantahala Capital Management, LLC	139,298	-6,562
0.16364 %	Jennison Associates LLC	138,241	37,345
0.16299 %	TD Asset Management Inc.	137,690	24,034
0.15856 %	BlackRock Advisors (UK) Limited	133,952	9,014
0.15420 %	Parkman Healthcare Partners LLC	130,265	-2,436
0.15015 %	HighVista Strategies LLC	126,845	0
0.14277 %	First Trust Advisors L.P.	120,614	1,076
0.14023 %	Two Sigma Investments, LP	118,469	-90,839
0.13062 %	Nicholas Investment Partners, L.P.	110,351	94,094
0.12962 %	Allianz Global Investors GmbH	109,505	0
0.12797 %	EAM Investors, LLC	108,110	20,448
0.12699 %	BlackRock Asset Management Ireland Limited	107,277	7,750
0.11074 %	Northern Trust Global Investments	93,555	-2,641
0.10942 %	Manulife Investment Management (North America) Limited	92,438	14,028
0.10618 %	Citi Investment Research (US)	89,698	34,444
0.10176 %	Rhumbline Advisers Ltd. Partnership	85,966	7,172
0.10073 %	Schweizerische Nationalbank	85,100	-21,900
0.10002 %	Hudson Bay Capital Management LP	84,500	49,500
0.09941 %	Wellington Management Company, LLP	83,984	83,984
0.09176 %	Qube Research & Technologies Ltd	77,516	42,162
0.09139 %	Parametric Portfolio Associates LLC	77,204	-397
0.08828 %	UBS O'Connor LLC	74,575	-51,574
0.08404 %	HOOPP Investment Management	71,000	71,000
0.08256 %	Goldman Sachs Asset Management, L.P.	69,749	-32,327
0.07694 %	MFS Investment Management	65,001	-11,145
0.07411 %	Credit Suisse Funds AG	62,610	1,300
0.07247 %	Campbell & Company, Inc.	61,226	29,536
0.07102 %	DWS Investment GmbH	60,000	57,038
0.06828 %	AllianceBernstein L.P.	57,680	7,140
0.06636 %	UBS Asset Management (Switzerland)	56,062	5,356
0.06539 %	Capstone Investment Advisors, LLC	55,239	55,239
0.06477 %	Mellon Investments Corporation	54,717	7,896
0.06271 %	State of Wisconsin Investment Board	52,976	-11,134
0.05919 %	Deka Vermögensmanagement GmbH	50,000	0
0.05854 %	Legal & General Investment Management Ltd.	49,452	-1,122
0.05738 %	Dimensional Fund Advisors, Ltd.	48,478	3,106
0.05724 %	California State Teachers Retirement System	48,359	-6,659

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Cyteir Therapeutics	공급업체고객	0,86	0,92	0,91	0,93	-	-
WuXi AppTec Co H	공급업체고객	0,20	0,69	-0,35	0,78	0,80	0,81
Roche Holding	공급업체고객	0,06	0,70	-0,49	0,19	-0,15	0,23
Novartis	공급업체고객	-0,08	0,14	-0,67	-0,64	-0,32	-0,13
Pfizer	공급업체고객	-0,54	0,59	-0,23	0,50	-0,35	0,22
GlaxoSmithKline	공급업체고객	-0,56	-0,56	-0,67	-0,51	-0,70	-0,39

What values and corporate philosophy does IDEAYA Biosciences represent?

IDEAYA Biosciences Inc represents a commitment to scientific innovation and improving patient outcomes. The company focuses on developing targeted oncology therapies by leveraging its expertise in synthetic lethality and immuno-oncology. IDEAYA embraces a corporate philosophy centered around collaboration, integrity, and patient-centricity. By actively partnering with leading biopharmaceutical companies and institutions, IDEAYA aims to accelerate the development of transformative medicines. The company's dedication to precision medicine and cutting-edge technologies drives its mission to address unmet needs in oncology and provide hope for patients worldwide. IDEAYA Biosciences Inc is dedicated to delivering value to patients, healthcare providers, and stakeholders through its innovative research and therapeutic advancements.

In which countries and regions is IDEAYA Biosciences primarily present?

IDEAYA Biosciences Inc is primarily present in the United States.

What significant milestones has the company IDEAYA Biosciences achieved?

IDEAYA Biosciences Inc has achieved several significant milestones. The company successfully completed its initial public offering in May 2019. IDEAYA Biosciences Inc also entered into a strategic collaboration with GlaxoSmithKline (GSK) in October 2019 to develop targeted therapies for solid tumors. They have advanced their oncology pipeline, with notable progress in their Synthetic Lethality programs, including the initiation of Phase 1/2 clinical trials. In addition, IDEAYA Biosciences Inc expanded its oncology collaboration with Novartis in December 2019. They have made substantial strides in their research and development efforts, bringing innovative and precision medicine approaches to cancer treatment.

What is the history and background of the company IDEAYA Biosciences?

IDEAYA Biosciences Inc is a clinical-stage oncology-focused precision medicine company. Founded in 2015, IDEAYA is dedicated to leveraging its Synthetic Lethality platform to develop personalized therapies for patients with genetically defined cancers. The company's innovative approach involves using biomarkers to identify patients who are most likely to respond to their targeted cancer therapies. IDEAYA's collaborative partnerships, such as the one with Pfizer, enable it to accelerate the development of its portfolio of drug candidates. With a strong track record and a commitment to improving patient outcomes, IDEAYA Biosciences Inc is well-positioned to make a positive impact in the field of precision oncology.

Who are the main competitors of IDEAYA Biosciences in the market?

The main competitors of IDEAYA Biosciences Inc in the market include leading biopharmaceutical companies such as Bristol-Myers Squibb, Novartis AG, Pfizer Inc, and Roche Holding AG. These companies also operate in the biotechnology sector and offer innovative solutions for various diseases and medical conditions. IDEAYA Biosciences Inc competes with these industry giants through its cutting-edge research and development, strategic partnerships, and focus on targeted therapies for oncology and immuno-oncology. By offering unique approaches to precision medicine, IDEAYA Biosciences Inc aims to carve a niche for itself in the competitive biopharmaceutical market.

In which industries is IDEAYA Biosciences primarily active?

IDEAYA Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of IDEAYA Biosciences?

IDEAYA Biosciences Inc is a precision medicine-focused biotechnology company. Their business model revolves around leveraging their expertise in synthetic lethality and cancer biology to discover and develop targeted oncology therapeutics. By combining their innovative drug discovery platforms and partnerships, IDEAYA aims to address specific genetic alterations in cancer cells. This approach allows them to develop personalized medicines for patients based on the underlying drivers of their disease. IDEAYA's business model is centered on advancing their pipeline of novel therapies and collaborating with strategic partners to bring innovative treatments to patients in need.

IDEAYA Biosciences 2024의 P/E 비율은 얼마입니까?

IDEAYA Biosciences의 P/E 비율은 -8.3입니다.

IDEAYA Biosciences 2024의 KUV는 얼마입니까?

IDEAYA Biosciences의 P/S 비율은 213.39입니다.

IDEAYA Biosciences의 AlleAktien 품질 점수는 얼마인가요?

IDEAYA Biosciences에 대한 AlleAktien 품질 점수는 3/10입니다.

IDEAYA Biosciences 2024의 매출은 얼마인가요?

예상되는 IDEAYA Biosciences 매출은 8.55 백만 USD입니다.

IDEAYA Biosciences 2024의 이익은 얼마인가요?

예상되는 IDEAYA Biosciences 이익은 -219.55 백만 USD입니다.

IDEAYA Biosciences은 무엇을 하나요?

IDEAYA Biosciences Inc is a leading biopharmaceutical company focused on the treatment of cancer. The company offers a wide range of products and services aimed at treating cancer at the cellular level. The company has an innovative business model based on the combination of three core elements: research and development, clinical trials, and partnerships. Research and Development IDEAYA Biosciences Inc focuses on developing drugs that have the potential to combat cancer at the cellular level. The company uses a range of technologies and methods to identify and validate potential drug candidates, including its proprietary platforms for drug discovery and development. These platforms enable the company to quickly and efficiently identify and develop promising new therapies. Clinical Trials IDEAYA Biosciences Inc conducts clinical trials to demonstrate the efficacy and safety of new drugs. The company is currently conducting clinical trials at multiple locations worldwide to advance its pipeline of innovative cancer therapies. The clinical trials focus on various types of cancer, such as prostate cancer, breast cancer, advanced melanoma, and others. Partnerships IDEAYA Biosciences Inc collaborates with various leading companies and universities to advance its research. The partnerships include strategic alliances, acquisitions, and collaboration in drug development and manufacturing. Through these partnerships, IDEAYA Biosciences Inc can leverage its resources and bring its products to market faster. Products IDEAYA Biosciences Inc has launched a wide range of products and services focused on cancer treatment. One product highlight, for example, is the proprietary/oncology inhibitor IDEA-316. This drug has shown promising results in preclinical development and has the potential to provide innovative solutions for cancer patients suffering from inhibitor resistance. Overall, IDEAYA Biosciences Inc has an innovative business model aimed at combating cancer at the cellular level. The combination of research and development, clinical trials, and partnerships enables the company to quickly and efficiently identify and develop promising new therapies to help cancer patients.

IDEAYA Biosciences 배당금은 얼마입니까?

IDEAYA Biosciences은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

IDEAYA Biosciences이 얼마나 자주 배당을 지급하나요?

IDEAYA Biosciences의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

IDEAYA Biosciences ISIN이 무엇입니까?

IDEAYA Biosciences의 ISIN은 US45166A1025입니다.

IDEAYA Biosciences WKN은 무엇인가요?

IDEAYA Biosciences의 WKN은 A2PJPB입니다.

IDEAYA Biosciences 티커는 무엇인가요?

IDEAYA Biosciences의 티커는 IDYA입니다.

IDEAYA Biosciences이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 IDEAYA Biosciences은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 IDEAYA Biosciences은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

IDEAYA Biosciences의 배당 수익률은 얼마입니까?

IDEAYA Biosciences의 현재 배당 수익률은 입니다.

IDEAYA Biosciences의 배당금은 언제 지급되나요?

IDEAYA Biosciences은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

IDEAYA Biosciences의 배당금은 얼마나 안전한가요?

IDEAYA Biosciences은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

IDEAYA Biosciences의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

IDEAYA Biosciences이(가) 속해 있는 섹터는 어디인가요?

IDEAYA Biosciences은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von IDEAYA Biosciences kaufen, um die vorherige Dividende zu erhalten?

IDEAYA Biosciences의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

IDEAYA Biosciences의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

IDEAYA Biosciences의 2023년도 배당금은 얼마였습니까?

2023년에 IDEAYA Biosciences는 0 USD를 배당금으로 지급했습니다.

IDEAYA Biosciences는 어떤 화폐로 배당금을 지급하나요?

IDEAYA Biosciences의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출	—
스코프 2 - 구매한 에너지로부터의 간접적인 배출	—
Scope 3 - 가치 창출 체인 내의 간접 배출	—
총 CO₂ 배출량	—
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	✅
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	❌
환경 친화적인 포장	❌
위험물질	❌
연료 소비량과 효율성	❌
물 사용량 및 효율성	❌

여성 직원 비율	42
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	❌
개인정보 보호 정책	—
작업 및 건강 보호	❌
카톨릭	✅

환경 보고	❌
이해관계자 참여	❌
콜백 정책	❌
카르텔법	❌

증권거래소	IDEAYA Biosciences 티커
프랑크푸르트	30J.F
뮌헨	30J.MU
NASDAQ	IDYA

IDEAYA Biosciences 티커	IDEAYA Biosciences FIGI
IDYA:US	BBG00CTZ4D83
IDYA:UA	BBG00P162WR7
IDYA:UC	BBG00P162WS6
IDYA:UN	BBG00P162WV2
IDYA:UP	BBG00P162WW1
IDYA:UB	BBG00P162WY9
IDYA:UM	BBG00P162X04
IDYA:UX	BBG00P162X13
IDYA:UD	BBG00P162X68
IDYA:UW	BBG00P162X86
IDYA:UF	BBG00P162X95
IDYA:VY	BBG00P162XB2
IDYA:VJ	BBG00P162XC1
IDYA:VK	BBG00P162XD0
IDYA:VF	BBG00P162XF8
30J:GR	BBG00P80MTL4
30J:GF	BBG00P80MTM3
30J:GS	BBG00P80MTR8
30J:GB	BBG00P80MTT6
30J:TH	BBG00P96RZQ6
IDYAEUR:XS	BBG00P976244
IDYAEUR:XH	BBG00P976271
IDYAEUR:XF	BBG00P976299
IDYAEUR:XE	BBG00P9762C5
IDYAEUR:XJ	BBG00P9762D4
IDYAEUR:XL	BBG00P9762F2
IDYAEUR:XG	BBG00P9762G1
IDYAEUR:XO	BBG00P9762H0
IDYAEUR:XA	BBG00P9762M4
IDYAEUR:E1	BBG00P9762N3
IDYAEUR:XT	BBG00P9762P1
IDYAEUR:XW	BBG00P9762Q0
IDYAEUR:XU	BBG00P9762R9
IDYAEUR:XV	BBG00P9762S8
IDYAEUR:XM	BBG00P9762T7
IDYAEUR:XQ	BBG00P9762V4
IDYAEUR:XX	BBG00P9762W3
IDYAEUR:XZ	BBG00P9762X2
IDYAEUR:EU	BBG00P9762Z0
IDYAUSD:XS	BBG00PBK0444
IDYAUSD:XH	BBG00PBK0471
IDYAUSD:XF	BBG00PBK0499
IDYAUSD:XE	BBG00PBK04C5
IDYAUSD:XJ	BBG00PBK04D4
IDYAUSD:XL	BBG00PBK04F2
IDYAUSD:XG	BBG00PBK04G1
IDYAUSD:XO	BBG00PBK04H0
IDYAUSD:XA	BBG00PBK04M4
IDYAUSD:E1	BBG00PBK04N3
IDYAUSD:XT	BBG00PBK04P1
IDYAUSD:XW	BBG00PBK04Q0
IDYAUSD:XU	BBG00PBK04R9
IDYAUSD:XV	BBG00PBK04S8
IDYAUSD:XM	BBG00PBK04T7
IDYAUSD:XQ	BBG00PBK04V4
IDYAUSD:XX	BBG00PBK04W3
IDYAUSD:XZ	BBG00PBK04X2
IDYAUSD:EU	BBG00PBK04Z0
30J:GZ	BBG00PPWQWB5
IDYAGBP:EP	BBG00RLVC9X9
IDYAGBP:EZ	BBG00RLVC9Z7
IDYAGBP:XS	BBG00RLVCB19
IDYAGBP:X2	BBG00RLVCB28
IDYAGBP:XH	BBG00RLVCB46
IDYAGBP:XF	BBG00RLVCB64
IDYAGBP:XE	BBG00RLVCB82
IDYAGBP:XJ	BBG00RLVCB91
IDYAGBP:XL	BBG00RLVCBB8
IDYAGBP:XG	BBG00RLVCBC7
IDYAGBP:XO	BBG00RLVCBD6
IDYAGBP:XA	BBG00RLVCBJ0
IDYAGBP:E1	BBG00RLVCBK8
IDYAGBP:XT	BBG00RLVCBL7
IDYAGBP:XW	BBG00RLVCBM6
IDYAGBP:XU	BBG00RLVCBN5
IDYAGBP:XV	BBG00RLVCBQ2
IDYAGBP:XM	BBG00RLVCBR1
IDYAGBP:XQ	BBG00RLVCBS0
IDYAGBP:XX	BBG00RLVCBT9
IDYAGBP:XZ	BBG00RLVCBV6
IDYAGBP:X1	BBG00RLVCBX4
IDYAGBP:EU	BBG00RLVCC17
IDYA:VG	BBG00X1PC159
IDYA:VP	BBG00X1SSFK8
30J:LA	BBG018H9RHY9
30J:LU	BBG018J3F1Q7

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커IDYA

ISINUS45166A1025

WKNA2PJPB

IDEAYA Biosciences 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

IDEAYA Biosciences 주가 이력

IDEAYA Biosciences 주식 매출, EBIT, 이익 US45166A1025 · A2PJPB

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

IDEAYA Biosciences 매출, 이익 및 EBIT 역사

IDEAYA Biosciences 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

IDEAYA Biosciences 주식 마진 US45166A1025 · A2PJPB

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

IDEAYA Biosciences 마진 역사

IDEAYA Biosciences 주식 매출, EBIT, 주당 순이익 US45166A1025 · A2PJPB

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

IDEAYA Biosciences 매출, 이익 및 EBIT 주당 역사

IDEAYA Biosciences 주식 및 주식 분석

IDEAYA Biosciences Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

IDEAYA Biosciences 역사적인 P/E, EBIT 및 P/S에 따른 평가

IDEAYA Biosciences 주식 수량 US45166A1025 · A2PJPB

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

IDEAYA Biosciences 수익 예상

IDEAYA Biosciences 수익 놀라움

Eulerpool ESG Scorecard© IDEAYA Biosciences 주식을 위해

Eulerpool World ESG Rating (EESG©)

39/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

IDEAYA Biosciences 주식 주주 구조

IDEAYA Biosciences 임원진 및 경영진

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
IDYA

ISIN
US45166A1025

WKN
A2PJPB